title: Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression.
abstract: To identify cellular promoters in a self-inactivating (SIN) lentiviral vector that might be beneficial in treating children with leukocyte adhesion deficiency type 1 (LAD-1), we tested lentiviral vectors with human CD11 and CD18 leukocyte integrin proximal promoter elements directing expression of canine CD18 in animals with canine LAD (CLAD). Lentiviral vectors with either the human CD11b (637 bp) proximal promoter or the human CD18 (1,060 bp) proximal promoter resulted in the highest percentages of CD18(+) CLAD CD34(+) cells in vitro. Subsequently, two CLAD dogs were infused with autologous CD34(+) cells transduced with the hCD11b (637 bp)-cCD18 vector, and two CLAD dogs were infused with autologous CD34(+) cells transduced with the hCD18 (1,060 bp)-cCD18 vector. Each dog received a nonmyeloablative dose of 200 cGy total body irradiation (TBI) before the infusion of transduced cells. The two CLAD dogs treated with the hCD18 (1,060 bp)-cCD18 vector, and one of the two dogs treated with the hCD11b (637 bp)-cCD18 vector, had reversal of the CLAD phenotype. These studies using endogenous leukocyte integrin proximal promoters represent an important step in the development of gene therapy for children with LAD-1.
authors.affiliation: Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1203, USA. huntermj@mail.nih.gov
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Hunter
authors.forename: Laura M
authors.initials: LM
authors.lastname: Tuschong
authors.forename: Cedar J
authors.initials: CJ
authors.lastname: Fowler
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Bauer
authors.forename: Tanya H
authors.initials: TH
authors.lastname: Burkholder
authors.forename: Dennis D
authors.initials: DD
authors.lastname: Hickstein
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000235:genetics; D039481:CD11b Antigen / Q000096:biosynthesis / Q000235:genetics*; D018821:CD18 Antigens / Q000096:biosynthesis / Q000235:genetics*; D004285:Dogs; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D018370:Leukocyte-Adhesion Deficiency Syndrome / Q000235:genetics / Q000628:therapy; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D011401:Promoter Regions, Genetic; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D014161:Transduction, Genetic / Q000379:methods; D016896:Treatment Outcome; D014916:Whole-Body Irradiation / Q000379:methods
chemical_list: D018952:Antigens, CD34; D039481:CD11b Antigen; D018821:CD18 Antigens